Company intelligence / Profile preview

PhosImmune

Charlottesville, Virginia, United States

Ownership: Private
Development stage: Other

Overview

PhosImmune commercialized a platform for phosphopeptide tumor target identification. No clinical stage programs advanced independently; technology was integrated into Agenus' pipeline upon acquisition.

Therapeutic areas: Oncology
Modalities: AntibodyMonoclonal antibodyBiologic
Industry: Drug Discovery Services

Partnerships

PureMHC

Beyond the preview

Go deeper on PhosImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhosImmune.

Explore the full profile